Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

The interventional oncology market valued at US$ 2.53 Billion in 2023, is forecasted to grow at a robust CAGR of 9.0%, reaching US$ 2.75 Billion in 2024 and an impressive US$ 4.24 Billion by 2029. The ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, toda ...

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

Discover why Exact Sciences, a leading oncology diagnostics company, may see growth in the cancer diagnostics market with its ...

Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...